It should be highlighted that in this study, the rate of EGFR status unknown patients was 65.1% and EGFR mutation was only 5.4%, which was much lower than our study, even lower than the EGFR positive rate in the overall NSCLC group. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.